Algernon Pharmaceuticals Plans Phase 2

May 31, 2026
Media Summary: CEO Chris Moreau discusses the recent Ifendprodil transaction with Seyltx and Interview with Christopher Moreau, CEO of Interview with CEO Christopher Moreau and host Cyndi Edwards regarding news about the next steps in

Algernon Pharmaceuticals Plans Phase 2 - Detailed Analysis & Overview

CEO Chris Moreau discusses the recent Ifendprodil transaction with Seyltx and Interview with Christopher Moreau, CEO of Interview with CEO Christopher Moreau and host Cyndi Edwards regarding news about the next steps in

Photo Gallery

Algernon Pharmaceuticals plans Phase 2 stroke and TBI study after successful DMT single dose study
Algernon Pharmaceuticals Announces Upcoming Phase 2b Chronic Cough Study of Ifenprodil.
Algernon Pharmaceuticals provides update on Phase 2B/3 study as they enroll 50th patient
Algernon Pharmaceuticals releases details of Phase 2b Chronic Cough Study of Ifenprodil
Algernon Pharmaceuticals begins screening patients for Phase 2 chronic cough and IPF study
Algernon Pharmaceuticals sees more positive date from Phase 2 study on Ifenprodil for IPF and Cough
Algernon Pharmaceuticals Update - IPF/Chronic Cough Studies
Algernon Pharmaceuticals (AGN) CEO Chris Moreau Outlines DMT Stroke Research and Ifendprodil Plans
Algernon Pharmaceuticals releases positive data from study on Ifenprodil for IPF and Chronic Cough
Algernon Pharmaceuticals receives US FDA clearance for Phase 2b/3 human study
Algernon Pharmaceuticals Update - Appointment of Top UK Stroke Experts
Algernon Pharmaceuticals gets green light from data and safety board to continue Phase 2b-3 study

Related Updates

Algernon Pharmaceuticals plans Phase 2 stroke and TBI study after successful DMT single dose study Algernon Pharmaceuticals Announces Upcoming Phase 2b Chronic Cough Study of Ifenprodil. Algernon Pharmaceuticals provides update on Phase 2B/3 study as they enroll 50th patient Algernon Pharmaceuticals releases details of Phase 2b Chronic Cough Study of Ifenprodil Algernon Pharmaceuticals begins screening patients for Phase 2 chronic cough and IPF study Algernon Pharmaceuticals sees more positive date from Phase 2 study on Ifenprodil for IPF and Cough Algernon Pharmaceuticals Update - IPF/Chronic Cough Studies Algernon Pharmaceuticals (AGN) CEO Chris Moreau Outlines DMT Stroke Research and Ifendprodil Plans Beating Psychic Types: The Hidden Strategies Proven To Work Escape The Ordinary: Affordable Housing In The Space Coast What's Really Behind Eminem's Explosive 'dob' Diss Track Forbes Says Bernie Sanders Is Worth How Much In 2025 – The Truth Revealed Mysterious Loofahs Appear On Cars Across The Country Overnight The Surprising Truth About Tipping: When To Give A Little Extra The Wayans Sisters You Need To Know In Hollywood QC Dispatch Obituaries: Remembering Our Loved Ones
Sponsored
Sponsored
View Detailed Profile
Algernon Pharmaceuticals plans Phase 2 stroke and TBI study after successful DMT single dose study

Algernon Pharmaceuticals plans Phase 2 stroke and TBI study after successful DMT single dose study

Algernon Pharmaceuticals

Algernon Pharmaceuticals Announces Upcoming Phase 2b Chronic Cough Study of Ifenprodil.

Algernon Pharmaceuticals Announces Upcoming Phase 2b Chronic Cough Study of Ifenprodil.

Interview with

Sponsored
Algernon Pharmaceuticals provides update on Phase 2B/3 study as they enroll 50th patient

Algernon Pharmaceuticals provides update on Phase 2B/3 study as they enroll 50th patient

Algernon Pharmaceutical

Algernon Pharmaceuticals releases details of Phase 2b Chronic Cough Study of Ifenprodil

Algernon Pharmaceuticals releases details of Phase 2b Chronic Cough Study of Ifenprodil

Algernon Pharmaceuticals

Algernon Pharmaceuticals begins screening patients for Phase 2 chronic cough and IPF study

Algernon Pharmaceuticals begins screening patients for Phase 2 chronic cough and IPF study

Algernon Pharmaceuticals

Sponsored
Algernon Pharmaceuticals sees more positive date from Phase 2 study on Ifenprodil for IPF and Cough

Algernon Pharmaceuticals sees more positive date from Phase 2 study on Ifenprodil for IPF and Cough

Algernon Pharmaceuticals

Algernon Pharmaceuticals Update - IPF/Chronic Cough Studies

Algernon Pharmaceuticals Update - IPF/Chronic Cough Studies

Algernon Pharmaceuticals

Algernon Pharmaceuticals (AGN) CEO Chris Moreau Outlines DMT Stroke Research and Ifendprodil Plans

Algernon Pharmaceuticals (AGN) CEO Chris Moreau Outlines DMT Stroke Research and Ifendprodil Plans

CEO Chris Moreau discusses the recent Ifendprodil transaction with Seyltx and

Algernon Pharmaceuticals releases positive data from study on Ifenprodil for IPF and Chronic Cough

Algernon Pharmaceuticals releases positive data from study on Ifenprodil for IPF and Chronic Cough

Algernon Pharmaceuticals

Algernon Pharmaceuticals receives US FDA clearance for Phase 2b/3 human study

Algernon Pharmaceuticals receives US FDA clearance for Phase 2b/3 human study

Algernon Pharmaceuticals

Algernon Pharmaceuticals Update - Appointment of Top UK Stroke Experts

Algernon Pharmaceuticals Update - Appointment of Top UK Stroke Experts

Algernon Pharmaceuticals

Algernon Pharmaceuticals gets green light from data and safety board to continue Phase 2b-3 study

Algernon Pharmaceuticals gets green light from data and safety board to continue Phase 2b-3 study

Algernon Pharmaceuticals

Algernon Pharmaceuticals receives ok from South Korea for phase two study of Ifenprodil

Algernon Pharmaceuticals receives ok from South Korea for phase two study of Ifenprodil

Algernon Pharmaceuticals

Algernon Pharmaceuticals Makes Major Headway Toward Clinical Trials for Treatment of Stroke Part 2

Algernon Pharmaceuticals Makes Major Headway Toward Clinical Trials for Treatment of Stroke Part 2

Algernon Pharmaceuticals

Algernon Pharmaceuticals DMT/Stroke Clinical Program

Algernon Pharmaceuticals DMT/Stroke Clinical Program

Join Christopher J. Moreau, CEO of

Algernon Pharmaceuticals Update with CEO Christopher Moreau

Algernon Pharmaceuticals Update with CEO Christopher Moreau

Interview with Christopher Moreau, CEO of

Market One Minute - Algernon Pharmaceuticals

Market One Minute - Algernon Pharmaceuticals

Market One Minute -

Algernon Pharmaceuticals Makes Major Headway Toward Clinical Trials for Treatment of Stroke Part 1

Algernon Pharmaceuticals Makes Major Headway Toward Clinical Trials for Treatment of Stroke Part 1

Algernon Pharmaceuticals

Algernon Pharmaceuticals DMT Stroke Program Update and Recap with CEO Christopher Moreau

Algernon Pharmaceuticals DMT Stroke Program Update and Recap with CEO Christopher Moreau

Interview with CEO Christopher Moreau and host Cyndi Edwards regarding news about the next steps in

Related Video Content

Flowers for Algernon - Wikipedia information

Flowers for Algernon is a short novelette [5] by American author Daniel Keyes, which he later expanded into a novel...

Flowers for Algernon by Daniel Keyes | Full Text information

Read about Flowers for Algernon by Daniel Keyes — analysis, themes, and discussion. A man's experimental journey from...

Algernon | Flowering Plant, Plant Genus, Plant Species | Britannica information

Algernon, fictional character, a witty man-about-town in Oscar Wilde ’s play The Importance Of Being Earnest (1895)....

Flowers for Algernon by Daniel Keyes | Goodreads information

Flowers for Algernon is a beautiful and poignant story. Daniel Keyes effectively teaches us about the issue of living...

Flowers for Algernon: Full Book Summary | SparkNotes information

A short summary of Daniel Keyes's Flowers for Algernon. This free synopsis covers all the crucial plot points of...